secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001213900-24-014197
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 5.06, 9.01, 5.02, 5.01, 5.03
LLM model:  deepseek-v4-flash:cloud@v2

CERO Therapeutics completes business combination with PBAX; raises $9.4M PIPE
-----------------------------------------------------------------------------

- Business combination closed Feb 14, 2024; PBAX merged with CERo, renamed CERO Therapeutics Holdings.
- Issued ~7.58M shares to CERo stockholders; 3.075M earnout shares subject to stock price/regulatory milestones.
- PIPE financing raised ~$9.4M via 12,580 Series A preferred shares and warrants; convertible bridge notes exchanged.
- Entered $25M equity line of credit with Keystone Capital; shares sold at 90% of VWAP, capped at 19.99%.
- Lock-up on ~673,504 shares for 180 days or until $12.50 VWAP for 20 days within 30 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/0001213900-24-014197-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024014197/ea193687-8k_phoenix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-014197

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer